Please ensure Javascript is enabled for purposes of website accessibility

Why Danaher Stock Crashed in February

By Lee Samaha - Mar 6, 2020 at 7:31AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare-focused company's stock got taken down with the rest of the market, but is the market being rational?

What happened

Shares in life sciences and diagnostics focused company Danaher Corporation (DHR 0.39%) slumped 10.1% in February according to data provided by S&P Global Market Intelligence. There's no point ignoring the elephant in the room. The stock's down move in February is correlated with the general market sell-off due to fears around the impact on global growth from the COVID-19 outbreak.

A gloved hand places a slide on a microscope.

Image source: Getty Images.

It may seem puzzling that the market should be so keen to sell off a healthcare stock that would likely see increased spending due to the high-profile spread of a disease, but in the short-term, markets are anything but rational.

To be fair, Danaher is unlikely to escape a negative impact in the short term. If it isn't supply chain disruptions, it's a potential drop in demand coming from a lack of activity. During the first-quarter earnings conference call, Danaher CEO Thomas Joyce discussed the matter in a positive light.

"Obviously, it's a very challenging situation to get a clear handle on in terms of what [the coronavirus'] overall impact is," he said. "We have not seen any specific impact to this point on our business." Clearly, matters have gotten worse since the end of January.

So what

Long-term investors who are confident that the COVID-19 outbreak will ultimately diminish in the same manner as previous respiratory illnesses like SARS and MERS won't be unduly worried by the stock price fall. On the contrary, they will see the outbreak as a catalyst for awareness around research and development and diagnostics in the healthcare sector.

Moreover, there's a lot to like about Danaher in 2020. The pending deal to buy General Electric's biopharma business looks like a great deal and Danaher has great sales momentum -- core revenue growth has been in the mid-single digits in every quarter since the end of 2017.

Now what

If you can stomach some market volatility, and you aren't worried about a long-term impact on the economy from COVID-19, this could be a very good buying opportunity for a stock with exciting long-term prospects. Alternatively, if the impact is lasting, it's unlikely that Danaher will escape the market malaise. Time will tell.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Danaher Corporation Stock Quote
Danaher Corporation
$252.86 (0.39%) $0.98
General Electric Company Stock Quote
General Electric Company
$63.69 (-3.32%) $-2.19

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.